8-K: NeOnc Technologies Appoints Amir Heshmatpour as President to Accelerate Clinical Initiatives

NeOnc Technologies Holdings, Inc. appoints Executive Chairman Amir Heshmatpour as President to enhance leadership and drive strategic and clinical advancements.

Summary

• NeOnc Technologies Holdings, Inc. has appointed Amir Heshmatpour, the current Executive Chairman, as the new President of the company.
• Heshmatpour will retain his role as Executive Chairman while taking on day-to-day leadership responsibilities.
• The appointment aims to accelerate the company's strategic and clinical initiatives.
• He will be paid $1 per month until his employment agreement is finalized.
• NeOnc has entered into an office lease for approximately 1,427 square feet of office space located at 23975 Park Sorrento, Calabasas, California 91302.
• The lease term is for 63 months, anticipated to commence on April 14, 2025.
• Monthly rent starts at $6,778.25 in April 2025 and increases annually.
• The company will also pay 1.40% of the building's operating expenses.
• AFH Holdings and Advisory, LLC, where Mr. Heshmatpour is the sole member and managing director, was engaged to assist NeOnc Technologies, Inc. in connection with its intent to effect a public listing and earned $500,000 during the year ended December 31, 2023.
• In February 2025, Mr. Heshmatpour advanced the Company approximately $300,000 which carries a 50% original issue discount (OID) on the principal.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with the appointment of a new president and a new office lease. However, the related-party transactions and short-term loans raise some concerns.

Positives

• The appointment of Amir Heshmatpour as President is expected to provide strong leadership and accelerate the company's strategic and clinical initiatives.
• The new office lease provides a physical location for the company's principal executive offices.
• The company has secured a worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.

Negatives

• The company's reliance on related-party transactions, particularly with AFH Holdings and Advisory, LLC, could raise concerns about potential conflicts of interest.
• The short-term loans with high original issue discounts (OID) indicate a need for capital and potentially unfavorable borrowing terms.
• The company's agreement to pay AFH a fee equal to 2% of the post-money valuation of the Company immediately after the consummation of the direct listing may be considered excessive.

Risks

• The company's success depends heavily on the clinical trials of NEO212 and NEO100, which are subject to inherent risks and uncertainties.
• The company's financial performance is subject to risks and uncertainties, including the ability to raise capital and generate revenue.
• The company's reliance on related-party transactions could expose it to potential conflicts of interest and regulatory scrutiny.

Future Outlook

The company aims to advance its clinical programs, with a specific emphasis on patient enrollment for its lead drug candidates NEO212 and NEO100, and deliver significant value to patients, providers, and shareholders.

Management Comments

• Dr. Thomas Chen, CEO of NeOnc, stated that Amir's appointment as President reflects their commitment to strong, visionary leadership as NeOnc advances its clinical programs.
• Amir Heshmatpour expressed his confidence in the company's ability to deliver significant value to patients, providers, and shareholders alike.

Industry Context

The announcement highlights NeOnc's focus on developing innovative treatments for central nervous system cancers, a field with significant unmet medical needs and commercial potential. The appointment of a seasoned executive like Heshmatpour suggests a strategic move to strengthen the company's leadership and accelerate its clinical development efforts.

Comparison to Industry Standards

• The lease terms for the office space appear to be within the typical range for commercial real estate in the Calabasas area.
• The related-party transactions, particularly the engagement of AFH Holdings, are not uncommon in smaller biotech companies but require careful scrutiny to ensure fairness and transparency.
• The company's focus on NEO100 and NEO212 aligns with the industry trend of developing targeted therapies for specific cancer types.
• The company's worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions is similar to other companies in the space.

Management Changes

Related Party Transactions

• AFH Holdings and Advisory, LLC, where Mr. Heshmatpour is the sole member and managing director, was engaged to assist NeOnc Technologies, Inc. in connection with its intent to effect a public listing and earned $500,000 during the year ended December 31, 2023.
• In February 2025, Mr. Heshmatpour advanced the Company approximately $300,000 which carries a 50% original issue discount (OID) on the principal.

Stakeholder Impact

• Shareholders may view the appointment of a new president as a positive step towards achieving the company's goals.
• Employees may experience changes in leadership and organizational structure.
• Customers (patients) may benefit from the accelerated development of new treatments.
• Suppliers and creditors may be affected by the company's financial performance and ability to meet its obligations.

Next Steps

• Finalize the employment agreement for Amir Heshmatpour.
• Continue clinical trials for NEO212 and NEO100, focusing on patient enrollment.
• Manage the new office space and associated expenses.

Key Dates

Keywords

NeOnc Technologies, Amir Heshmatpour, President, Office Lease, Clinical Trials, NEO212, NEO100, AFH Holdings, Related Party Transactions, Biopharmaceutical